Basiliximab for the treatment of steroid-resistant ulcerative colitis: Further experience in moderate and severe disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 10, 2006, Pages 1435-1442

  Creed, T J ^a,b,d   Probert, C S J ^b   Norman, M N ^a   Moorghen, M ^b   Shepherd, N A ^c   Hearing, S D ^b   Dayan, C M ^a   Mountford, R A ^e   Brown, J ^e   Valori, R ^e   Shaw, I ^e   Harvey, R ^e   Anderson, J ^e   Crossley, I ^e   Smithson, J ^e   Hughes, S ^e   Davis, M ^e   Perry, J ^e   Robertson, D ^e   Farrant, J M ^e   Linehan, J ^e   Panagiotakopoulos, D ^e   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; HYDROCORTISONE; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FEVER; HERPES ZOSTER; HUMAN; LETHARGY; LOW BACK PAIN; MALE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECTUM BIOPSY; REMISSION; SCORING SYSTEM; ULCERATIVE COLITIS; ULCERATIVE COLITIS SYMPTOM SCORE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREDNISOLONE; QUALITY OF LIFE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646232018     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02904.x     Document Type: Article

References (35)

1. Truelove S Witts L. Cortisone in ulcerative colitis. Final report on a therapeutic trial BMJ 1955 ii 1041 8
2. Faubion W Loftus E Harmsen W Zinsmeister A Sandborn W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 2001 121 255 60
3. Hyde G Thillainayagam A Jewell D. Intravenous cyclosporine as rescue therapy in severe ulcerative colitis: time for a re-appraisal Eur J Gastroenterol Hepatol 1998 10 411 3
4. Plevy S Salzberg S Regueiro M. A humanised anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid refractory UC: preliminary results of a phase 1 study Gastroenterology 2003 124 A7
5. Gordon FH Hamilton MI Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin Aliment Pharmacol Ther 2002 16 699 705
6. Madsen SM Schlichting P Davidsen B et al. An open-labeled, randomized study comparing systemic interferon-[alpha]-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis Am J Gastroenterol 2001 96 1807 15
7. Tilg H Vogelsang H Ludwiczek O et al. A randomised placebo controlled trial of pegylated interferon-alpha in active ulcerative colitis Gut 2003 52 1728 33
8. Schreiber S Fedorak R Wild GE. Safety and tolerance of rhIL-10 treatment in patients with mild/moderate active ulcerative colitis Gastroenterology 1998 114 A1080 1
9. Probert CSJ Hearing SD Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial Gut 2003 52 998 1002
10. Sands BE Tremaine WJ Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study Inflamm Bowel Dis 2001 72 83 8
11. Sandborn WJ Rachmilewitz D Hanauer S et al. Infliximab induction and maintenance therapy for ulcerative colitis DDW 2005 (Abstract ID 688)
12. Jarnerot G Hertervig E Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 2005 128 1085 811
13. Rutgeerts P Sandborn WJ Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 2005 353 2462 76
14. Rutgeerts P Feagan BG Olson A et al. A randomised placebo controlled trial of infliximab therapy for active ulcerative colitis: ACT 1 Trial DDW 2005 (Abstract ID 689)
15. Kam JC Szefler SJ Surs W Sher ER Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids J Immunol 1993 151 3460 6
16. Goleva E Kisich KO Leung DYM. A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance J Immunol 2002 169 5934 40
17. Norman M Hearing SD. Glucocorticoid resistance - what is known Curr Opin Pharmacol 2002 2 723 9
18. Adu D Cockwell P Ives NJ Shaw J Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials BMJ 2003 326 789
19. Creed TJ Norman MR Probert CSJ et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis Aliment Pharmacol Ther 2003 18 65 75
20. Munkholm P Langholz E Davidsen M Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 1994 35 360 2
21. Truelove SC Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1974 303 1067 70
22. Schroeder KW Tremaine WJ Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 1987 317 1625 9
23. Baron J Connell A Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis BMJ 1964 1 89 92
24. Travis SP Farrant JM Ricketts C et al. Predicting outcome in severe ulcerative colitis Gut 1996 38 905 10
25. Onrust S Wiseman L. Basiliximab Drugs 1999 57 207 13
26. Irvine E. A quality of life index for inflammatory bowel disease Can J Gastroenterol 1993 7 155 9
27. Riley SA Mani V Goodman MJ Dutt S Herd ME. Microscopic activity in ulcerative colitis: what does it mean Gut 1991 32 174 8
28. Lichtiger S Present DH Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 1994 330 1841 5
29. van Gossum A Schmidt A Adler M et al. Short and long term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis Acta Gastroenterol Belg 1997 60 197 200
30. Cohen RD Stein R Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience Am J Gastroenterol 1999 94 1587 92
31. D'Haens G Lemmens L Vandeputte L et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 2001 120 1323 9
32. van Assche G D'haens G Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis(1) Gastroenterology 2003 125 1025 31
33. Haslam N Hearing SD Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects Eur J Gastroenterol Hepatol 2000 12 657 60
34. Boggi U Danesi R Vistoli F et al. A benefit-risk assessment of basiliximab in renal transplantation Drug Saf 2004 27 91 106
35. van Assche G Dalle I Noman M et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis Am J Gastroenterol 2003 98 369 76